MichaelPulsipherMD

Pediatric Hematology & Oncology • Salt Lake City, UT

Pediatric Hematologic Oncology

Division Chief, Pediatric Hematology and Oncology, Intermountain Primary Children's Hospital. Director, Intermountain and Huntsman Cancer Institute Children's and Adolescent Cancer Initiative IPCH/HCI Presidential Chair in Cancer Research at the Spencer Fox Eccles School of Medicine at the University of Utah

Join to view full profile

Dr. Pulsipher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pulsipher's full profile

Already have an account?

Office
2000 Circle of Hope Dr.
Rm. 3515
Salt Lake City, UT 84112
Phone+1 801-646-4211

Summary

I am Division Chief of the Pediatric Hematology and Oncology Program at Intermountain Primary Children's Hospital and Director of the Child and Adolescent Cancer Research Initiative at the Huntsman Cancer Institute at the Spencer Fox Eccles School of Medicine at the University of Utah. I have expertise in cell therapy and BMT and a past group Chair of the Pediatric Transplantation and Cellular Therapy Consortium – an 86-member international clinical trials group.

Education & Training

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1993 - 1996
Children's Hospital of PhiladelphiaResidency, Pediatrics, 1990 - 1993
Stanford University School of MedicineClass of 1990

Certifications & Licensure

UT State Medical License 1998 - 2026
CA State Medical License 2015 - 2025
ID State Medical License 2013 - 2015
PA State Medical License 1992 - 1994
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Lifetime Achievement Award Pediatric Transplantation and Cellular Therapy Consortium, 2020

Clinical Trials

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 2
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Start of enrollment: 2003 May 01
Completed
Phase 2
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Start of enrollment: 2007 Mar 01
Completed
Phase 3
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Start of enrollment: 2006 Dec 01
Completed
Phase 3
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases Start of enrollment: 2001 Dec 01
Recruiting
Phase 1, Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Natural History Study of SCID Disorders Start of enrollment: 2010 Sep 02
Enrolling by invitation
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2010 Nov 01
Completed
Phase 3
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2010 Dec 01
Completed
Phase 2
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
Terminated
Phase 3
Patients Treated for SCID (1968-Present) Start of enrollment: 2011 May 15
Enrolling by invitation
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant Start of enrollment: 2012 Jun 01
Completed
Abatacept as GVHD Prophylaxis Phase 2 Start of enrollment: 2013 Feb 01
Active, not recruiting
Phase 2
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients Start of enrollment: 2013 Aug 01
Completed
Phase 3
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 Start of enrollment: 2014 Feb 02
Completed
Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995 Start of enrollment: 2014 Jun 01
Enrolling by invitation
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children Start of enrollment: 2015 Oct 01
Enrolling by invitation
Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Start of enrollment: 2019 Aug 29
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

13 citations
KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial.
Michael A Pulsipher, Kwang W Ahn, Nancy J Bunin, Nahal Lalefar, Eric Anderson
Blood. 2022-12-15
2 citations
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication.
Michael D Keller, Stefan A Schattgen, Shanmuganathan Chandrakasan, E Kaitlynn Allen, Mariah A Jensen-Wachspress
Nature Communications. 2024-03-29
2 citations
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II intervent...
Michael D Keller, Patrick J Hanley, Yueh-Yun Chi, Paibel Aguayo-Hiraldo, Christopher C Dvorak
Nature Communications. 2024-04-18

Abstracts/Posters

Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy
Michael A. Pulsipher, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
Michael A. Pulsipher, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Immunologic and Brain Bases of Neurotoxicity Associated with CAR T-Cell Therapy
Michael A. Pulsipher, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses
Michael A. Pulsipher, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
Michael A. Pulsipher, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lower Hematopoietic Progenitor Cell Counts and Yields at Subsequent Donations Is Influenced By a Shorter Inter-Donation Interval between the First and Subsequent Mobil...
Michael A. Pulsipher, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Prepa...
Michael A. Pulsipher, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A Panoply of Immunotherapies for Adult B-Lineage Acute Lymphocytic Leukemia
60th American Society of Hematology Annual Meeting - 12/3/2018
A Panoply of Immunotherapies for Adult B-Lineage Acute Lymphocytic Leukemia
60th American Society of Hematology Annual Meeting - 12/1/2018
Weighty Choices: Selecting Optimal G-CSF Doses for Stem Cell Mobilization to Optimize Yield
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphobl...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
ASPHO's 26th Annual Meeting
American Society of Pediatric Hematology/Oncology( ASPHO), Miami, Florida - 4/24/2013
Join now to see all

Press Mentions

Treating ALL with Cellular and Targeted Immunotherapies Reduces the Need for TransplantOctober 2nd, 2019
Immunotherapies in ALL: What’s Best and What’s Next?March 6th, 2019
Bright Future for Gene Therapy in Hematologic MalignanciesFebruary 27th, 2018
Join now to see all

Grant Support

Blood And Marrow Transplant Clinical Trials NetworkNational Heart, Lung, And Blood Institute2011
LATE Effects After Pediatric HSCT: State Of The Science, Future DirectionsNational Cancer Institute2011
Rdsafe: A Multi-Institutional Study Of HSC Donor Safety And Quality LifeNational Heart, Lung, And Blood Institute2009–2011
Blood And Marrow Transplant Clinical Trials NetworkNational Heart, Lung, And Blood Institute2009–2010
Gene Transfer And Functional Studies Of Fanconi AnemiaNational Heart, Lung, And Blood Institute1997